فهرست نشریات علمی دسترسی آزاد ایران

Objective: The primary outcome was the management of acute agitation, as measured by the RichmondAgitation-Sedation Scale (RASS). Secondary outcomes included the incidence of adverse effects and the timeto onset of the therapeutic effect.Methods: This randomized clinical trial was conducted between March 2021 and March 2022. Participantswere recruited from patients presenting with acute agitation who required pharmacological intervention atEmam Reza and Shahid Hasheminejad hospitals (Mashhad, Iran). Eligible participants were adults aged 18 to65 years. Using a block randomization method with a block size of four, patients were assigned to receive either5 mg of intravenous (IV) haloperidol or 2 mg/Kg of IV ketamine. Data were analyzed using SPSS software(version 22).Results: A total of 120 participants were randomized. The majority were male, comprising 43 (73%) in thehaloperidol group and 45 (75%) in the ketamine group. The mean age was 45.42±16.65 in the ketamine groupand 48.28±16.75 years in the haloperidol group (p=0.34). In the haloperidol group, the mean admission RASSscore was 1.73±0.75, which decreased to 0.07±1.25 post-intervention. In the ketamine group, the mean admissionRASS score was 1.58±0.61, which improved to -0.92±1.19 following treatment.Conclusion: Ketamine demonstrated a faster onset of action in managing acute agitation than haloperidol.These findings suggested that ketamine might represent a viable first-line therapeutic